Anis Assad

Anis Assad

Auto-generated profile, based on publicly available information

Anis Assad

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in BJU International
Verified
Journal Article
Open access
AAAnis Assad
Anis Assad
BRBrendan Raizenne
Brendan Raizenne
MYMohammed El Mehdi El Yamani
Mohammed El Mehdi El Yamani
ASAlmousa Saud
Almousa Saud
SBSeth K. Bechis
Seth K. Bechis
NBNaeem Bhojani
Naeem Bhojani
Objective: To assess the impact of kidney stone disease (KSD) and its treatment on the health‐related quality of life (HRQOL) of high‐risk stone formers with hyperparathyroidism, renal tubular acidosis, malabsorptive disease, and medullary sponge kidney. Patients and Methods: The Wisconsin Stone Quality of Life questionnaire was used to evaluate HRQOL in 3301 patients with a history of KSD from 16 institutions in North America between 2014 and 2020. Baseline characteristics and medical history were collected from patients, while active KSD was confirmed through radiological imaging. The high‐risk group was compared to the remaining patients (control group) using the Wilcoxon rank‐sum test. Results: Of 1499 patients with active KSD included in the study, the high‐risk group included 120 patients. The high‐risk group had significantly lower HRQOL scores compared to the control group ( P < 0.01). In the multivariable analyses, medullary sponge kidney disease and renal tubular acidosis were independent predictors of poorer HRQOL, while alkali therapy was an independent predictor of better HRQOL (all P < 0.01). Conclusions: Among patients with active KSD, high‐risk stone formers had impaired HRQOL with medullary sponge kidney disease and renal tubular acidosis being independent predictors of poorer HRQOL. Clinicians should seek to identify these patients earlier as they would benefit from prompt treatment and prevention.

25 July 2023 in Cancer Epidemiology
Verified
Journal Article
Closed access
LSLukas Scheipner
Lukas Scheipner
CGCristina Cano Garcia
Cristina Cano Garcia
FBFrancesco Barletta
Francesco Barletta
RIReha-Baris Incesu
Reha-Baris Incesu
Simone MorraSimone Morra
Simone Morra
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

23 April 2024 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
AAAnis Assad
Anis Assad
FBFrancesco Barletta
Francesco Barletta
RIReha-Baris Incesu
Reha-Baris Incesu
LSLukas Scheipner
Lukas Scheipner
SMSimone Morra
Simone Morra
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

20 August 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
AAAnis Assad
Anis Assad
RIReha-Baris Incesu
Reha-Baris Incesu
Simone MorraSimone Morra
Simone Morra
LSLukas Scheipner
Lukas Scheipner
ABAndrea Baudo
Andrea Baudo
PKPierre I Karakiewicz
Pierre I Karakiewicz
Context: Although complete surgical resection provides the only means of cure in adrenocortical carcinoma (ACC), the magnitude of the survival benefit of adrenalectomy in metastatic ACC (mACC) is unknown. Objective: This work aimed to assess the effect of adrenalectomy on survival outcomes in patients with mACC in a real-world setting. Methods: Patients with mACC aged 18 years or older with metastatic ACC at initial presentation who were treated between 2004 and 2020 were identified within the Surveillance, Epidemiology, and End Results database (SEER 2004-2020), and we tested for differences according to adrenalectomy status. Intervention included primary tumor resection status (adrenalectomy vs no adrenalectomy). Kaplan-Meier plots, multivariable Cox regression models, and landmark analyses were used. Sensitivity analyses focused on use of systemic therapy, contemporary (2012-2020) vs historical (2004-2011), single vs multiple metastatic sites, and assessable specific solitary metastatic sites (lung only and liver only). Results: Of 543 patients with mACC, 194 (36%) underwent adrenalectomy. In multivariable analyses, adrenalectomy was associated with lower overall mortality without (hazard ratio [HR]: 0.39; P < .001), as well as with 3 months' landmark analyses (HR: 0.57; P = .002). The same association effect with 3 months' landmark analyses was recorded in patients exposed to systemic therapy (HR: 0.49; P < .001), contemporary patients (HR: 0.57; P = .004), historical patients (HR: 0.42; P < .001), and in those with lung-only solitary metastasis (HR: 0.50; P = .02). In contrast, no statistically significant association was recorded in patients naive to systemic therapy (HR: 0.68; P = .3), those with multiple metastatic sites (HR: 0.55; P = .07), and those with liver-only solitary metastasis (HR: 0.98; P = .9). Conclusion: The present results indicate a potential protective effect of adrenalectomy in mACC, particularly in patients exposed to systemic therapy and those with lung-only metastases.

26 December 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
RIReha-Baris Incesu
Reha-Baris Incesu
FBFrancesco Barletta
Francesco Barletta
CGCristina Cano Garcia
Cristina Cano Garcia
LSLukas Scheipner
Lukas Scheipner
Simone MorraSimone Morra
Simone Morra
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

30 October 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
LSLukas Scheipner
Lukas Scheipner
RIReha-Baris Incesu
Reha-Baris Incesu
Simone MorraSimone Morra
Simone Morra
ABAndrea Baudo
Andrea Baudo
AAAnis Assad
Anis Assad
PKPierre I. Karakiewicz
Pierre I. Karakiewicz